I agree Doolen:

 

If i were to write a report, I would rate the stock a buy precisely because of the great # of opportunities [catalysts] to provide nice upside to the $80-$82 pt.  I believe POM filings [Europe and US] are baked in, but approvals [Rev and Abraxane] and data readouts [apremilast + many others] are the ones to pop the stock.  With an accelerated Pom filing in US soon, could we be looking @ a FDA decision in 2012 on it?  the approval pops the stock and even chatter leading up to it.

 

I'd keep the PT low to be 'conservative'  -- like typical CELG guidance [ha!]

 

And completely agree...  Many of the catalysts are NON Revlimid...  which provide a stronger basis for P/E expansion. 

 

Look forward to the next 21 months full of catalysts.

 

 value